The tech – BRS 3000 – allows users to specify precise breathing profiles that – according to Copley – more closely mimic patient use of inhalers in the real-world.
It has a maximum inhalation volume of 5 litres and has flow rate and flow rate acceleration capabilities that allow for “the demands of MDI and DPI testing, when powerful inhalation-only manoeuvres are required.”
The system – which will be launched at Respiratory Drug Delivery (RDD) in San Diego, US in May – is designed as a companion technology to the BRS 2000 nebulizer testing platform that UK-based Copley rolled out in 2011.